ClearPoint Neuro Raises ATM Offering Capacity to $150 Million With Stifel
ClearPoint Neuro (CLPT) increased its ATM offering capacity to $150M from $50M via an amended agreement with Stifel. The company can sell shares through Stifel, with $27.5M available under the current prospectus. Additional sales require a new supplement. CLPT controls timing, price, and size of sales, paying up to 3% in commissions. The amendment was signed and effective on Nov 18, 2026.
How this was made

The 30-second read
Why it matters
By increasing the aggregate proceeds limit to $150M, ClearPoint Neuro expands its ability to raise capital on demand through Stifel. This can affect valuation through dilution expectations, even if no shares are sold immediately.
Market read
Traders may reassess dilution risk and financing runway expectations based on the larger ATM capacity and the remaining amount available under the current prospectus supplement.
What to watch
The article notes about $27.5M is currently available under the existing prospectus supplement, so near-term issuance may be constrained until a new supplement is filed for additional sales.
Background
At-the-market (ATM) equity programs allow issuers to sell shares gradually through a sales agent, typically to fund operations without a single large issuance event.
Ticker impact
ClearPoint Neuro amended its ATM equity sales agreement with Stifel to raise the aggregate sales proceeds cap from $50M to $150M.
Likely mild downside or volatility as the market prices in greater potential share issuance under the higher ATM cap.
The filing is a capital-raising mechanism expansion, not an executed sale. However, raising the cap to $150M can shift dilution expectations and affect sentiment, especially for growth-stage issuers.
Market effects
Adds to the broader biotech and healthcare small-cap financing backdrop where ATM expansions can signal ongoing capital needs.
No direct regional market linkage beyond typical US small-cap equity financing effects.
Limited, as this is a US-listed issuer-specific capital markets action.
Counterpoint
The higher ATM cap may not translate into immediate selling; the company may only draw as needed, limiting dilution impact.
Key entities
- issuerClearPoint Neuro, Inc.
Subject of the amended ATM equity offering sales agreement.
- counterpartyStifel
Sales agent under the ATM equity offering agreement.


